1-11 of 11
Manasee V. Shah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Maintenance Therapy in Patients with FLT3 -ITD-Mutation-Positive Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: Real-World Survival

Hongbo Yang, Yan Song, James D. Griffin, Manasee V. Shah, Jonathan Freimark, Andrew Chilelli
Journal: Blood
Blood (2021) 138 (Supplement 1): 693.
https://doi.org/10.1182/blood-2021-145790
Published: 2021
Journal Articles

Symptoms and Impacts Reported By Patients with Acute Myeloid Leukemia (AML) in Remission Post-Stem Cell Transplant

David Cella, Thomas W. LeBlanc, Manasee V. Shah, Anna de la Motte, Farah Toublan, Kimberly Kelly
Journal: Blood
Blood (2021) 138 (Supplement 1): 278.
https://doi.org/10.1182/blood-2021-145393
Published: 2021
Journal Articles

Patient Reported Outcomes in Patients with Newly Diagnosed FLT3 mut+ acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone

Eunice S. Wang, Michael Heuser, Pau Montesinos, Elizabeth Shima Rich, Ruishan Wu, Bhavik J. Pandya, Manasee V. Shah
Journal: Blood
Blood (2021) 138 (Supplement 1): 3058.
https://doi.org/10.1182/blood-2021-144977
Published: 2021
Journal Articles

Patient and Physician Preferences for Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients Not Candidates for Intensive Chemotherapy

Mo Zhou, Hongbo Yang, Yan Song, Deborah A. Marshall, James D. Griffin, Lalit Saini, Manasee V. Shah
Journal: Blood
Blood (2021) 138 (Supplement 1): 4047.
https://doi.org/10.1182/blood-2021-145385
Published: 2021
Journal Articles

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3 -Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Hongbo Yang, PhD, Andy Garnham, MSc, Manasee V. Shah, MPH, Amer M. Zeidan, MBBS, MHS
Journal: Blood
Blood (2020) 136 (Supplement 1): 7.
https://doi.org/10.1182/blood-2020-136184
Published: 2020
Journal Articles

Pain and Opioid Use in Patients with FLT3 Mutation-Positive Relapsed/Refractory AML: A Subanalysis of Patient-Reported Outcomes from the Admiral Trial

David Cella, PhD, Ellen Ritchie, MD, Arnaud Pigneux, MD PhD, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V. Shah, MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-134389
Published: 2020
Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 5085.
https://doi.org/10.1182/blood-2019-123811
Published: 2019
Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3859.
https://doi.org/10.1182/blood-2019-123819
Published: 2019
Journal Articles

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

David Cella, PhD, Ellen K. Ritchie, MD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3850.
https://doi.org/10.1182/blood-2019-123790
Published: 2019
Journal Articles

The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3 -Mutated ( FLT3 mut+ ) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Ellen K. Ritchie, MD, David Cella, PhD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 1332.
https://doi.org/10.1182/blood-2019-123779
Published: 2019
Journal Articles

Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3 -Mutated ( FLT3 mut ) and FLT3 -Wild Type ( FLT3 wt ) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study

James D. Griffin, MD, Manasee V Shah, MPH, Yan Song, PhD, Hongbo Yang, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4824.
https://doi.org/10.1182/blood-2018-99-110871
Published: 2018